Reinsberg, S A
Sohaib, S A
Charles-Edwards, E M
Christmas, T J
Thompson, A C
Bailey, M J
Corbishley, C M
Leach, Martin O
Dearnaley, David P
AffiliationAcademic Department of Radiotherapy and Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK. Andrew.Jackson@manchester.ac.uk
MetadataShow full item record
AbstractRadiotherapy dose escalation improves tumour control in prostate cancer but with increased toxicity. Boosting focal tumour only may allow dose escalation with acceptable toxicity. Intensity-modulated radiotherapy can deliver this, but visualization of the tumour remains limiting. CT or conventional MRI techniques are poor at localizing tumour, but dynamic contrast-enhanced MRI (DCE-MRI) may be superior. 18 patients with prostate cancer had T(2) weighted (T2W) and DCE-MRI prior to prostatectomy. The prostate was sectioned meticulously so as to achieve accurate correlation between imaging and pathology. The accuracy of DCE-MRI for cancer detection was calculated by a pixel-by-pixel correlation of quantitative DCE-MRI parameter maps and pathology. In addition, a radiologist interpreted the DCE-MRI and T2W images. The location of tumour on imaging was compared with histology, and the accuracy of DCE-MRI and T2W images was then compared. Pixel-by-pixel comparison of quantitative parameter maps showed a significant difference between the benign peripheral zone and tumour for the parameters K(trans), v(e) and k(ep). Calculation of areas under the receiver operating characteristic curve showed that the pharmacokinetic parameters were only "fair" discriminators between cancer and benign gland. Interpretation of DCE-MRI and T2W images by a radiologist showed DCE-MRI to be more sensitive than T2W images for tumour localization (50% vs 21%; p = 0.006) and similarly specific (85% vs 81%; p = 0.593). The superior sensitivity of DCE-MRI compared with T2W images, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in prostate cancer.
CitationDynamic contrast-enhanced MRI for prostate cancer localization. 2009, 82 (974):148-56 Br J Radiol
JournalThe British Journal of Radiology
- Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.
- Authors: Nguyen HT, Pohar KS, Jia G, Shah ZK, Mortazavi A, Zynger DL, Wei L, Clark D, Yang X, Knopp MV
- Issue date: 2014 Jun
- Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
- Authors: Selnæs KM, Heerschap A, Jensen LR, Tessem MB, Schweder GJ, Goa PE, Viset T, Angelsen A, Gribbestad IS
- Issue date: 2012 Nov
- Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
- Authors: Ocak I, Bernardo M, Metzger G, Barrett T, Pinto P, Albert PS, Choyke PL
- Issue date: 2007 Oct
- Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation.
- Authors: Fennessy FM, Fedorov A, Penzkofer T, Kim KW, Hirsch MS, Vangel MG, Masry P, Flood TA, Chang MC, Tempany CM, Mulkern RV, Gupta SN
- Issue date: 2015 Sep
- Volumetry of the dominant intraprostatic tumour lesion: intersequence and interobserver differences on multiparametric MRI.
- Authors: Harvey H, Orton MR, Morgan VA, Parker C, Dearnaley D, Fisher C, deSouza NM
- Issue date: 2017 Mar